Ligand Pharmaceuticals Inc.
10275 Science Center Drive
San Diego,
CA 92121-1117
United States - Map
Phone: 858-550-7500
Fax: 858-550-1826
Web Site: http://www.ligand.com
| Ligand Pharmaceuticals Incorporated, a biotechnology company, focuses on the discovery and development of pharmaceuticals for the critical unmet medical needs in the United States. It offers Avinza for the treatment of chronic pain; and Eltrombopag/Promacta for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP). The companys products under food and drug administration review comprise Bazedoxifene and Lasofoxifene to treat osteoporosis; and Eltrombopag/Revolade for the treatment of ITP. Its products under Phase III include Bazedoxifene/Premarin for menopausal symptoms; and Eltrombopag to treat hepatitis C and chronic liver disease. The companys products under Phase II consist of PS433540, a dual acting receptor agonist that targets the angiotensin and endothelin receptors; LGD-4665 for the treatment of ITP; Eltrombopag to treat oncology related thrombocytopenia; PS291822 to prevent COPD and asthma; and PS540446 for the treatment of psoriasis and atherosclerosis. Ligands products under Phase I comprise Eltrombopag to treat oncology related thrombocytopenia; PS095760 for leukemia; PS386113 and PS873266 for inflammation; PS948115 to treat respiratory diseases; PS248288 for the treatment of metabolic related diseases; and PS178990 for muscle wasting. Its products under preclinical stage consist of BACE inhibitor for the treatment of Alzheimers disease; LGD-4033 for muscle wasting; CCR1 antagonist and glucocorticoid receptor modulator for inflammation; Erythropoietin receptor agonist for hematological indications; and receptor modulators for androgen independent prostate cancer. Ligand has research and development collaborations with pharmaceutical companies, including GlaxoSmithKline; Wyeth; Pfizer, Inc.; Schering-Plough Ltd.; Bristol-Myers Squibb Company; Cephalon, Inc.; Celgene Corporation; and Trevena. The company was founded in 1987 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. John L. Higgins , 38
Chief Exec. Officer, Pres and Exec. Director |
$
606.00K |
$
0 | Mr. John P. Sharp CPA, 44
Chief Financial Officer, Principal Accounting Officer and VP of Fin. |
$
317.00K |
$
0 | Mr. Charles S. Berkman J.D., 40
VP, Sec. and Gen. Counsel |
$
302.00K |
$
0 | Dr. Martin D. Meglasson Ph.D., 59
VP of Discovery Research |
$
411.00K |
$
0 | Dr. Syed Kazmi Ph.D., MBA, 52
VP of Bus. Devel. & Strategic Planning |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.03% Nasdaq 0.00%
Profile
